# US 10,980,871 B2 · Vaccine compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,980,871 B2
- Document ID: US10980871B2
- Status: Granted
- Kind: B2
- Application number: 16/611,256
- Filed: 2018-05-08
- Published: 2020-05-21
- Granted: 2021-04-20
- Earliest claimed: 2017-05-08
- Assignees: iosBio Ltd
- Applicants: iosBio Ltd
- Inventors: Jeffrey Drew
- Web page: https://patentgrep.com/patent/US10980871B2

## CPC

- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16251: Methods of production or purification of viral material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to an immunogenic composition comprising influenza virus antigens derived from at least 5 influenza virus strains and one or more compounds of formula (I) or physiologically acceptable salts or esters thereof: wherein: R1 represents hydrogen or C1-6 alkyl; R2 represents C1-6 alkyl; and R3 represents C1-6 alkyl. The invention also relates to methods of preparing the immunogenic composition, to pharmaceutical and vaccine compositions comprising the immunogenic composition and to use of the immunogenic, pharmaceutical and vaccine compositions for preventing influenza virus infection.

## Claims

### Claim 1

An immunogenic composition comprising influenza virus antigens derived from at least 5 influenza virus strains and one or more compounds of formula (I) or a physiologically acceptable salt or ester thereof:
wherein:
R1 represents hydrogen or C1-6 alkyl;
R2 represents C1-6 alkyl; and
R3 represents C1-6 alkyl.

### Claim 2 (depends on 1)

The immunogenic composition according to claim 1, comprising influenza virus antigens derived:
from 20 or less influenza virus strains, or
from at least 6 influenza virus strains, or
from 8 to 18 influenza virus strains, or
from 14 to 18 influenza virus strains, or
from 15 influenza virus strains, or
at least 2 influenza virus types, or
from at least 2 subtypes of influenza virus type A.

### Claim 3 (depends on 1)

The immunogenic composition according to claim 1, comprising at least one influenza virus antigen derived from a type A influenza virus strain and at least one influenza virus antigen derived a type B influenza virus strain.

### Claim 4 (depends on 1)

The immunogenic composition according to claim 1, comprising influenza virus antigens derived from at least 2 subtypes of influenza virus type A.

### Claim 5 (depends on 1)

The immunogenic composition according to claim 1, comprising at least one influenza virus antigen derived from a H1N1 subtype of a type A influenza virus strain and at least one influenza virus antigen derived a H3N2 subtype of a type A influenza virus strain.

### Claim 6 (depends on 1)

The immunogenic composition according to claim 1, comprising influenza virus antigens derived from one or more of the following influenza virus strains:
07/102 A/Solomon Islands/3/2006 (H1N1) (IVR-145),
02/336 A/New Caledonia,
08/100 A/Brisbane/59/2007 (IVR-148)(H1N1),
08/140 B/Florida/4/2006,
08/184 B/Malaysia/2506/2004,
09/174 A/California/7/09 (H1N1)(NYMCX-179A),
09/310 A/Wisconsin/15/2009 (H3N2)(NYMCX-183),
12/110 B/Wisconsin/1/2010 (Cell Derived),
12/112 A/Victoria/210/2009 (H3N2)(NYMCX-187),
12/114 A/Victoria/361/2011 (H3N2)(IVR-165),
13/134 B/Massachusetts/02/2012,
13/162 A/Texas/50/2012 (H3N2)(NYMCX-223A),
13/234 B/Brisbane/60/08,
14/252 B/Phuket/3073/2013, and
14/254 A/Switzerland/9715293/2013 (NIB88).

### Claim 7 (depends on 1)

The immunogenic composition according to claim 1, which comprises one or two compounds of formula (I) or physiologically acceptable salts or esters thereof.

### Claim 8 (depends on 1)

The immunogenic composition according to claim 1, which comprises dimethylglycine or a pharmaceutically acceptable salt or ester thereof.

### Claim 9 (depends on 8)

The immunogenic composition according to claim 8, which comprises dimethylglycine and trimethylglycine, or pharmaceutically acceptable salts or esters of one or both thereof.

### Claim 10 (depends on 1)

The immunogenic composition according to claim 1, in which the influenza virus antigens have previously undergone (a) freezing, (b) heat-treating and/or (c) freeze-drying when in an aqueous composition additionally comprising the or each compound.

### Claim 11 (depends on 1)

The immunogenic composition according to claim 1, in which the immunogenic composition further comprises one or more sugars.

### Claim 12 (depends on 1)

The immunogenic composition according to claim 1, in which the immunogenic composition comprises one sugar which is mannitol.

### Claim 13 (depends on 1)

The immunogenic composition according to claim 1, in which the immunogenic composition further comprises an adjuvant.

### Claim 14 (depends on 13)

The immunogenic composition according to claim 13, in which the adjuvant is an aluminium salt adjuvant.

### Claim 15 (depends on 1)

An immunogenic composition according to claim 1, obtainable by a method comprising (a) freezing, (b) heat-treating, and/or (c) freeze-drying (i) a single aqueous composition which comprises the influenza virus antigens and the compound(s), or (ii) two or more aqueous compositions, each of which comprises at least one influenza virus antigen and at least one compound(s), and subsequently combining the resulting treated compositions.

### Claim 16

A method of inducing an immune response against an influenza virus in a subject, which method comprises administering to the subject an effective amount of an immunogenic composition, the composition comprising influenza virus antigens derived from at least 5 influenza virus strains and one or more compounds of formula (I) or a physiologically acceptable salt or ester thereof:
wherein:
R1 represents hydrogen or C1-6 alkyl;
R2 represents C1-6 alkyl; and
R3 represents C1-6 alkyl.

### Claim 17

A method of preventing an influenza virus in a subject, which method comprises administering to the subject an effective amount of an immunogenic composition, the composition comprising influenza virus antigens derived from at least 5 influenza virus strains and one or more compounds of formula (I) or a physiologically acceptable salt or ester thereof:
wherein:
R1 represents hydrogen or C1-6 alkyl;
R2 represents C1-6 alkyl; and
R3 represents C1-6 alkyl.
